178 related articles for article (PubMed ID: 32404956)
41. Acral lentiginous melanoma with multiple bone metastasis: case report.
Chen PT; Manvar K; Chaudhry R; Wu R; Wang JC
Pan Afr Med J; 2023; 45():141. PubMed ID: 37808429
[TBL] [Abstract][Full Text] [Related]
42. Metastatic Acral lentiginous melanoma: A case report and review.
Ahuja G; Kim JH; Tran JF; Nnorom S; Ali A; Ibrahim M; Okoye GA; Shokrani B; Dunmore-Griffith J; Geter K; Frederick WAI; Wilson L
J Natl Med Assoc; 2022 Jun; 114(3):290-294. PubMed ID: 35221075
[TBL] [Abstract][Full Text] [Related]
43. Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma.
Sheen YS; Liao YH; Lin MH; Chiu HC; Jee SH; Liau JY; Chang YL; Chu CY
PLoS One; 2016; 11(1):e0147431. PubMed ID: 26796627
[TBL] [Abstract][Full Text] [Related]
44. Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America.
Castaneda CA; Torres-Cabala C; Castillo M; Villegas V; Casavilca S; Cano L; Sanchez J; Dunstan J; Calderon G; De La Cruz M; Cotrina JM; Gomez HL; Galvez R; Abugattas J
Clin Transl Oncol; 2017 Dec; 19(12):1478-1488. PubMed ID: 28577153
[TBL] [Abstract][Full Text] [Related]
45. Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma.
Castaneda CA; Castillo M; Torres-Cabala C; Bernabe LA; Casavilca S; Villegas V; Sanchez J; de la Cruz M; Dunstan J; Cotrina JM; Gomez HL; Chavez C; Landa-Baella MP; Tello K; Felix BF; Abugattas J
Clin Transl Oncol; 2019 Sep; 21(9):1127-1134. PubMed ID: 30778854
[TBL] [Abstract][Full Text] [Related]
46. Acral lentiginous melanoma: indolent subtype with long radial growth phase.
Kim JY; Choi M; Jo SJ; Min HS; Cho KH
Am J Dermatopathol; 2014 Feb; 36(2):142-7. PubMed ID: 24556899
[TBL] [Abstract][Full Text] [Related]
47. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract][Full Text] [Related]
48. Acral lentiginous melanoma in the Turkish population and a new dermoscopic clue for the diagnosis.
Ozdemir F; Errico MA; Yaman B; Karaarslan I
Dermatol Pract Concept; 2018 Apr; 8(2):140-148. PubMed ID: 29785333
[TBL] [Abstract][Full Text] [Related]
49. Acral melanoma: correlating the clinical presentation to the mutational status.
Ravaioli GM; Dika E; Lambertini M; Chessa MA; Fanti PA; Patrizi A
G Ital Dermatol Venereol; 2019 Oct; 154(5):567-572. PubMed ID: 29512974
[TBL] [Abstract][Full Text] [Related]
50. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
51. Acral lentiginous melanoma. A clinicopathologic entity.
Krementz ET; Feed RJ; Coleman WP; Sutherland CM; Carter RD; Campbell M
Ann Surg; 1982 May; 195(5):632-45. PubMed ID: 7073361
[TBL] [Abstract][Full Text] [Related]
52. Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, With Mutations Distinct From V600E/V600K.
Fernandes M; Barcelos D; Comodo AN; Guimarães DP; Lopes Carapeto FC; Cardili L; de Sousa Morães L; Cerutti Ap J; Landman Ap G
Am J Dermatopathol; 2019 Oct; 41(10):733-740. PubMed ID: 31021835
[TBL] [Abstract][Full Text] [Related]
53. Marker Protein Expression Combined With Expression Heterogeneity is a Powerful Indicator of Malignancy in Acral Lentiginous Melanomas.
Cintra Lopes Carapeto F; Neves Comodo A; Germano A; Pereira Guimarães D; Barcelos D; Fernandes M; Landman G
Am J Dermatopathol; 2017 Feb; 39(2):114-120. PubMed ID: 28134728
[TBL] [Abstract][Full Text] [Related]
54. Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma.
Susok L; Gambichler T
J Cancer Res Clin Oncol; 2022 Feb; 148(2):497-502. PubMed ID: 33856527
[TBL] [Abstract][Full Text] [Related]
55. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
56. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
57. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
Jamerson T; Rebecca VW; Aguh C
J Natl Med Assoc; 2022 Feb; 114(1):7-11. PubMed ID: 34509302
[TBL] [Abstract][Full Text] [Related]
58. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
59. Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan.
Wada M; Ito T; Tsuji G; Nakahara T; Hagihara A; Furue M; Uchi H
J Dermatol; 2017 Aug; 44(8):932-938. PubMed ID: 28342269
[TBL] [Abstract][Full Text] [Related]
60. Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy?
Ito T; Wada M; Nagae K; Nakano-Nakamura M; Nakahara T; Hagihara A; Furue M; Uchi H
J Am Acad Dermatol; 2015 Jan; 72(1):71-7. PubMed ID: 25455840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
